News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
3i Group plc has partnered with a former Lonza executive to create a ‘pure-play, patient-centric and sustainable’ biologics drug product contract development and manufacturing organization (CDMO).
The US medical research agency plans to offer funding over five years through a newly launched consortium, expected to include 30 sites across the country.
The UK government accuses Valneva of being in breach of its supply agreement obligations - something the company 'strenuously denies' - as it cancels its COVID-19 vaccine contract.
AbbVie is aligning with Regenxbio to develop and commercialize a potential one-time gene therapy for the treatment of chronic retinal diseases.